Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website https://jocmr.elmerjournals.com

Original Article

Volume 18, Number 2, February 2026, pages 83-98


Investigating Factors Influencing Disease Progression in Patients With Non-Alcoholic Fatty Liver Disease

Figures

↓  Figure 1. The overall of the study methods.
Figure 1.
↓  Figure 2. The result in step 1 of the study.
Figure 2.
↓  Figure 3. The survival analysis of the primary outcomes for each cluster.
Figure 3.
↓  Figure 4. The survival analysis of the secondary outcomes for each cluster.
Figure 4.
↓  Figure 5. Comparison of the ROC curve between cluster 1 and cluster 2. ROC: receiver operating characteristic.
Figure 5.

Tables

↓  Table 1. Incidence Rates and Hazard Ratios of Clinical Outcomes Between the Four Clusters
 
Clinical endpoints Clusters Number of events Follow-upa Incidence rateb Hazard ratio (95% CI)
Crude P-value
aFollow-ups were presented by person-years. bIncidence rates were presented by per 10,000 person-years. CI: confidence interval; HCC: hepatocellular carcinoma; LC: liver cirrhosis.
Primary 1 2 53 7,171 73.91 1.000 (Reference) -
1 102 2,006 508.47 6.918 (4.963, 9.645) < 0.0001
3 53 7,001 75.70 1.027 (0.702, 1.502) 0.8920
4 14 1,002 139.72 1.896 (1.052, 3.417) 0.0332
Primary 2 2 25 7,171 34.86 1.000 (Reference) -
1 28 2,006 139.58 3.964 (2.310, 6.803) < 0.0001
3 21 7,001 30.00 0.861 (0.482, 1.539) 0.6143
4 2 1,002 19.96 0.572 (0.135, 2.414) 0.4467
LC 2 19 7,171 26.50 1.000 (Reference) -
1 18 2,006 89.73 3.320 (1.741, 6.331) 0.0003
3 14 7,001 20.00 0.756 (0.379, 1.507) 0.4262
4 2 1,002 19.96 0.750 (0.175, 3.219) 0.6987
HCC 2 6 7,210 8.32 1.000 (Reference) -
1 12 2,024 59.29 7.097 (2.661, 18.928) < 0.0001
3 8 7,032 11.38 1.370 (0.475, 3.950) 0.5596
4 1 1,00 9.97 1.200 (0.145, 9.972) 0.8657
All-cause mortality 2 32 7,219 44.33 1.000 (Reference) -
1 85 2,049 414.84 9.554 (6.360, 14.350) < 0.0001
3 33 7,052 46.80 1.056 (0.650, 1.718) 0.8249
4 13 1,005 129.35 2.934 (1.540, 5.589) 0.0011
Liver-associated mortality 2 2 7,219 2.77 1.000 (Reference) -
1 4 2,049 19.52 7.459 (1.364, 40.786) 0.0204
3 0 7,052 0.00 NA NA
4 0 1,005 0.00 NA NA

 

↓  Table 2. Cluster 1 Compared With Cluster 2 (17 Variables of the Full Model)
 
Full model Cluster 1 (n = 658) Cluster 2 (n = 2,048) Variables type Odds ratio, 95% CI P-value Estimate (β)
Odds ratios for continuous variables are presented using clinically meaningful increments (e.g., per 10 units) to enhance clinical interpretability (except for hemoglobin (g/dL), for which a one-unit increment may be clinically substantial). BUN: blood urea nitrogen; CI: confidence interval; CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; Hgb: hemoglobin; LDL-C: low-density lipoprotein cholesterol; PTTp: partial thromboplastin time, plasma; RDW-SD: red cell distribution width-standard deviation.
Intercept 12.3011
Age (years) 67.9 (59.70, 75.90) 55.3 (43.65, 63.9) Explanatory 1.77 (1.51, 2.10) < 0.0001 0.0576
Chronic kidney disease 137 (20.82) 39 (1.90) Explanatory 4.521 (2.028, 10.074) 0.0002 1.5086
Other urinary system disease 172 (26.14) 49 (2.39) Explanatory/exploratory 6.894 (3.285, 14.470) < 0.0001 1.9307
Sodium chloride 473 (71.88) 378 (18.46) Unknown/exploratory 10.497 (6.750, 16.325) < 0.0001 2.3511
Metformin 228 (34.65) 307 (14.99) Explanatory 3.877 (2.382, 6.311) < 0.0001 1.3551
PTTp (s) 27.75 (26.56, 29.58) 27.62 (26.87, 28.70) Explanatory/exploratory 7.31 (3.98, 13.35) < 0.0001 0.1988
LDL-C (mg/dL) 92.95 (71.00, 111.20) 108.86 (92.45, 125.45) Explanatory/exploratory 0.75 (0.69, 0.82) < 0.0001 −0.0282
pCO2 (mm Hg) 40.98 (38.00, 43.80) 42.24 (39.86, 44.44) Explanatory/exploratory 0.23 (0.15, 0.36) < 0.0001 −0.1475
Glucose level (mg/dL) 123 (104, 159) 109 (101, 124) Explanatory/exploratory 1.23 (1.16, 1.29) < 0.0001 0.0203
CRP (mg/L) 11.06 (3.18, 33.27) 8.81 (3.59, 19.56) Explanatory 1.16 (1.08, 1.26) < 0.0001 0.0152
Total protein (mg/dL) 17.8 (10.68, 34.56) 16.42 (10.6, 30.2) Explanatory/exploratory 1.04 (1.01, 1.06) 0.0026 0.00358
Lymphocyte (%) 21.83 (14.60, 27.20) 27.34 (23.44, 30.96) Explanatory/exploratory 0.21 (0.15, 0.29) < 0.0001 −0.1564
Hgb (g/dL) 12.20 (11.00, 13.10) 14.23 (13.50, 15.10) Explanatory/exploratory 0.175 (0.140, 0.220) < 0.0001 −1.7410
RDW-SD (fL) 43.40 (41.80, 45.60) 42.25 (41.00, 43.52) Explanatory/exploratory 9.91 (4.66, 21.1) < 0.0001 0.2298
BUN (mg/dL) 17.10 (13.00, 24.30) 14.11 (12.22, 16.40) Explanatory/exploratory 2.79 (1.98, 3.87) < 0.0001 0.1023
eGFR (mL/min/1.73 m2) 70.20 (48.80, 88.90) 90.75 (77.30, 104.70) Explanatory/exploratory 0.78 (0.73, 0.85) < 0.0001 −0.0238
Urine creatinine (mg/dL) 108.68 (79.44, 143.70) 126.28 (101.08, 151.46) Explanatory/exploratory 0.90 (0.86, 0.95) < 0.0001 −0.0100

 

↓  Table 3. The First Sensitivity Analysis Cluster 1 Compared With Cluster 2 (17 Variables of Full Model)
 
Variables Variables type Odds ratio, 95% CI P-value Estimate (β)
Odds ratios for continuous variables are presented using clinically meaningful increments (e.g., per 10 units) to enhance clinical interpretability (except for hemoglobin (g/dL), for which a one-unit increment may be clinically substantial). BUN: blood urea nitrogen; CKD: chronic kidney disease; CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; Hgb: hemoglobin; LDL-C: low-density lipoprotein cholesterol; PTTp: partial thromboplastin time, plasma; RDW-SD: red cell distribution width-standard deviation.
Intercept 15.8739
Age (years) Explanatory 1.77 (1.51, 2.10) < 0.0001 0.0576
CKD Explanatory 4.521 (2.028, 10.074) 0.0002 0.7543
Other urinary system disease Explanatory/exploratory 6.894 (3.285, 14.470) < 0.0001 0.9653
Sodium chloride Unknown/exploratory 10.497 (6.750, 16.325) < 0.0001 1.1756
Metformin Explanatory 3.877 (2.382, 6.311) < 0.0001 0.6776
PTTp (s) Explanatory/exploratory 7.31 (3.98, 13.35) < 0.0001 0.1988
LDL-C (mg/dL) Explanatory/exploratory 0.75 (0.69, 0.82) < 0.0001 −0.0282
pCO2 (mm Hg) Explanatory/exploratory 0.23 (0.15, 0.36) < 0.0001 −0.1475
Glucose level (mg/dL) Explanatory/exploratory 1.23 (1.16, 1.29) < 0.0001 0.0203
CRP (mg/L) Explanatory 1.16 (1.08, 1.26) < 0.0001 0.0152
Total protein (mg/dL) Explanatory/exploratory 1.04 (1.01, 1.06) 0.0026 0.00358
Lymphocyte (%) Explanatory/exploratory 0.21 (0.15, 0.29) < 0.0001 −0.1564
Hgb (g/dL) Explanatory/exploratory 0.175 (0.140, 0.220) < 0.0001 −1.7410
RDW-SD (fL) Explanatory/exploratory 9.91 (4.66, 21.1) < 0.0001 0.2298
BUN (mg/dL) Explanatory/exploratory 2.79 (1.98, 3.87) < 0.0001 0.1023
eGFR (mL/min/1.73 m2) Explanatory/exploratory 0.78 (0.73, 0.85) < 0.0001 −0.0238
Urine creatinine (mg/dL) Explanatory/exploratory 0.90 (0.86, 0.95) < 0.0001 −0.0100

 

↓  Table 4. The Category of the Clusters in the Secondary Sensitivity Analysis
 
New clusters (seven clusters) Old clusters (five clusters)
0 1 2 3 4 Total
0 11 0 0 0 0 11
0.18 0 0 0 0 0.18
100 0 0 0 0
100 0 0 0 0
1 0 16 1,846 139 13 2,014
0 0.27 30.93 2.33 0.22 33.74
0 0.79 91.66 6.9 0.65
0 2.04 73.99 5.97 3.71
2 0 0 0 0 315 315
0 0 0 0 5.28 5.28
0 0 0 0 100
0 0 0 0 90
3 0 71 1 3 1 76
0 1.19 0.02 0.05 0.02 1.27
0 93.42 1.32 3.95 1.32
0 9.03 0.04 0.13 0.29
4 0 505 173 193 8 879
0 8.46 2.9 3.23 0.13 14.73
0 57.45 19.68 21.96 0.91
0 64.25 6.93 8.29 2.29
5 0 176 412 883 7 1,478
0 2.95 6.9 14.79 0.12 24.76
0 11.91 27.88 59.74 0.47
0 22.39 16.51 37.95 2
6 0 18 63 1109 6 1,196
0 0.3 1.06 18.58 0.1 20.04
0 1.51 5.27 92.73 0.5
0 2.29 2.53 47.66 1.71
Total 11 786 2495 2327 350 5,969
0.18 13.17 41.8 38.98 5.86 100